Participant flow

Paclitaxel and Carboplatin in Treating Patients With Persistent or Recurrent Stage III or Stage IV Uterine Cancer · Source last updated 2018-09-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Paclitaxel 175 mg/m2 IV over 3 hours followed by Carboplatin AUC = 6 IV over 30 minutes repeated every 21 days until disease progression or adverse effects prohibit further therapy

   id

   FG000

   title

   Paclitaxel Followed by Carboplatin

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         8

      type

      Refused further treatment

   2. reasons

      1. group Id

         FG000

         num Subjects

         12

      type

      Adverse Event

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Death

   4. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Other, Not Specified

   5. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Patient never treated

   6. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Ineligible

   milestones

   1. achievements

      1. comment

         All patients enrolled on study

         group Id

         FG000

         num Subjects

         55

      type

      STARTED

   2. achievements

      1. comment

         Completed regimen due to progression

         group Id

         FG000

         num Subjects

         15

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice